Sisram Med Ltd (SRAMF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Leaders Management. We can start. Good afternoon, investors and analysts. Welcome to SysRomatic's H1 2016 Interim Adults Earning Call. Today we will share with you the operating results of our company's key business progress and future development strategy for H1 this year. We have the management, including Mr. Lior Moshe Dayan, Chairman, Mr. Eyal Ben David, CEO, Mr. Jiahong Li, Co-CEO and CFO. I'm your moderator. Fan Hui, Director of IRIRD. This event is equipped with simultaneous invitation. Participants may listen on either English or Chinese channel. The first senior executives will share their remarks, followed by Q&A. We welcome your questions. Now, let's welcome Mr. Liu, our chairman, to begin. Please go ahead, Liu. Good day, everyone. Thank you very much for joining. As we open today's call, I'd like to share the board's perspective on the industry's direction and Cicerum's place within it. The fundamentals of medical aesthetics remain strong. Patient awareness is rising, treatment adoption is broadening, more medical professionals are entering the field, and innovation remains vibrant across technologies, injectables, and digital solutions. As the industry matures, the source of competitive advantage is changing with it. It is no longer about any single product. It's increasingly about the ability to deliver integrated solutions, execute consistency, and create long-term value across categories, technologies, and markets. That is why CISRM has spent the past several years building and why we will believe we are well positioned for the industry's next phase. Our international performance outside North America was a clear highlight in the first half, with strong demand across Asia Pacific, Europe, and the Middle East. Asia Pacific is now our largest and fastes...